{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:34:45Z","timestamp":1760661285208,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115391","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:49:20Z","timestamp":1743094160000},"page":"115391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Daratumumab for high-risk smoldering multiple myeloma \u2013 Are we there yet?"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-3342","authenticated-orcid":false,"given":"Bhavesh","family":"Mohan Lal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115391_bib1","doi-asserted-by":"crossref","unstructured":"Thorsteinsd\u00f3ttir S., G\u00edslason G.K., Aspelund T., R\u00f6gnvaldsson S, \u00d3skarsson J\u00de, Sigur\u00f0ard\u00f3ttir G\u00c1, et al. Prevalence of smoldering multiple myeloma based on nationwide screening [published correction appears in Nat Med. 2023 Dec; 29(12):3269. doi: 10.1038\/s41591-023-02308-5]. Nat Med 2023;29(2):467\u2013472. doi:10.1038\/s41591-022-02183-6.","DOI":"10.1038\/s41591-022-02183-6"},{"issue":"25","key":"10.1016\/j.ejca.2025.115391_bib2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115391_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102272","article-title":"Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey","volume":"65","author":"Mohyuddin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2025.115391_bib4","article-title":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma Published online December 9","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2025.115391_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1182\/blood.2021011670","article-title":"How I approach smoldering multiple myeloma [published correction appears in Blood. 2023 Mar 16;141(11):1366. doi: 10.1182\/blood.2022019523]","volume":"140","author":"Vaxman","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2025.115391_bib6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib\u00a0thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115391_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2025.115391_bib8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ejca.2025.115391_bib9","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","article-title":"Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"8","author":"Ebraheem","year":"2024","journal-title":"Blood Adv"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:48:05Z","timestamp":1760640485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":9,"alternative-id":["S0959804925001728"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115391","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daratumumab for high-risk smoldering multiple myeloma \u2013 Are we there yet?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115391"}}